FY profit warning sends Evotec's shares to 10-yr lows

Evotec SE

14/07/2026 08:42

Updates shares; adds further analyst comment in bullets 2 and 4, milestones in bullets 1 and 7
** Shares in Evotec EVTG.DE plummet about 31% to their lowest price in about 10 years after a profit warning
** Kempen says the second consecutive year of a FY guidance cut at mid-year creates an issue with reliably quantifying future incoming streams
** The German drug discovery firm sees FY revenue of €570-610 million ($649-695 million) vs €700-780 million previously; it cites delays into 2027 to large strategic partnerships 

    ** Deutsche Bank qualifies the outlook cut as a "large profit warning" on delayed revenues and negotiations
** "Despite management's confidence that the existing strategic programmes and the pipeline are delayed, not lost, we think it will have a tough time convincing the market as such," RBC says
** RBC adds Q2 represents a clear deterioration, citing revenue 16% below consensus, while a local trader describes Q2 preliminary report as "ugly"
** Evotec shares are on track for their worst day in almost two years
($1 = 0.8777 euros)

(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))